Welcome to our dedicated page for Biophytis Sa SEC filings (Ticker: BPTSY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biophytis SA filings document its foreign private issuer reporting for an ADR linked to a clinical-stage biotechnology company focused on age-related diseases. The company files Form 6-K reports that furnish press releases, interim financial reporting, meeting results, and other information distributed by the French issuer.
The filing record addresses BIO101 program disclosures, sarcopenia and obesity development updates, strategic and co-development agreements, capital increases, warrants, convertible debt repayment, bond financing amendments, and shareholder governance matters. These disclosures also show how the company reports financing activity and program spending alongside its Euronext Growth Paris ordinary-share listing and OTC ADS program.
Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.
Biophytis S.A. filed a Form 6-K to share a press release dated September 15, 2025. The company reports it has secured public funding in Brazil for an obesity phase 2 trial and has signed agreements with leading local clinical partners to conduct this study.
Biophytis S.A. filed a Form 6-K to share a press release dated September 15, 2025. The company reports it has secured public funding in Brazil for an obesity phase 2 trial and has signed agreements with leading local clinical partners to conduct this study.